Meet Remix™

Jeff Goater is a Venture Partner at The Column Group (TCG). Previously, Jeff served as interim Chief Executive Officer of the TCG portfolio company Atavistik Bio and before that Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously he spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy. Jeff holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester.

Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.

Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.

Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.

Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.

Matt Patterson is a biotechnology executive with more than 30 years of experience in the research, development, and commercialization of innovative therapeutics. Matt most recently served as Chairman and CEO of Iris Medicine, Inc. from January 2022 until April 2024. In 2012 Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception until its acquisition by Astellas Pharma Inc. in January 2020. Mr. Patterson was also Chairman of the Board of Directors at Audentes and formerly served as President until May 2018. Previously Mr. Patterson worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed. Matt is Chairman of the Board of Directors at Vor Biopharma, Inc. He also served as a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader
regenerative medicine sector, from 2015-2021, and was Chairman in 2019 and 2020. Mr. Patterson received his Bachelor’s degree in Biochemistry from Bowdoin College.

Dr. Koehler brings over 20 years of experience leading clinical and regulatory strategy operations for biotechnology and pharmaceutical companies focused on oncology research and development. She is currently the Chief Medical Officer of Repare Therapeutics, a clinical-stage precision oncology company. Dr. Koehler has also held executive and medical leadership roles at numerous companies, including Pfizer, AstraZeneca, Bicycle Therapeutics, and GlaxoSmithKline. Additionally, Dr. Koehler has served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh and the director of the Bone Marrow Transplant Program and associate professor at St. Christopher’s Hospital in Philadelphia. She is a board-certified hematology/oncology physician, holding an M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland. Dr. Koehler currently serves as an independent director on the board of directors at Ikena Oncology and Abdera Therapeutics.